Immunotherapy / PD-L1 inhibitorPhase 3 trialInvestigational
Atezolizumab
How it works
Blocks the PD-L1 receptor on cancer cells, allowing immune cells to recognize and attack them.
Cancer types
Efficacy
In clinical trials, patients treated with atezolizumab had a median overall survival of approximately 10.3 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| New Treatment Combination Shows Promise for Colon Cancer Patients | Colorectal Cancer | phase-3 | The 3-year disease-free survival was 86.3% in the atezolizumab-mFOLFOX6 group, as compared with 76.2% in the mFOLFOX6 group. | Source → |
| Pegylated Liposomal Doxorubicin and Immunotherapy in Recurrent Ovarian Cancer | Ovarian Cancer | phase-2 | — | Source → |
| Testing a New Treatment for Extensive Stage Small Cell Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Testing Atezolizumab with Radiation for Early Non-Small Cell Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Radiation Therapy Followed by Atezolizumab in Non-small Cell Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Testing Atezolizumab and Bevacizumab in Rare Solid Tumors | Lung Cancer | phase-2 | — | Source → |
| Testing Temozolomide and Atezolizumab for Metastatic or Recurrent Small Cell Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Atezolizumab Dosing Study for Various Cancers | Lung Cancer | phase-1 | — | Source → |
| Atezolizumab for Metastatic Colon Cancer | Colorectal Cancer | phase-3 | — | Source → |
| Testing Atezolizumab in Early-Stage Cutaneous Melanoma | Melanoma | phase-1 | — | Source → |
| Cost of Lung Cancer Treatments Compared | Lung Cancer | observational | — | Source → |
| Rare Side Effects from Cancer Treatment | Lung Cancer | observational | — | Source → |
| Testing Atezolizumab with Chemoradiation for Limited Stage Small Cell Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| PD-L1 Assays May Predict Benefit of Cancer Treatment | Lung Cancer | review | — | Source → |
| Atezolizumab plus chemotherapy effective in Japanese patients with advanced lung cancer | Lung Cancer | observational | Twelve-month OS rates were 62.9% (atezo + CnP), 72.1% (atezo + PP), and 68.3% (atezo + bev + CP). | Source → |
| Combining Atezolizumab with Bevacizumab and Chemotherapy for Recurrent Ovarian Cancer | Ovarian Cancer | phase-3 | The hazard ratio for overall survival was 0.83 (95% CI, 0.68 to 1.01; p = .06; median 14.2 months with atezolizumab and 13.0 months with placebo) | Source → |
| Atezolizumab Monotherapy Window in Triple-Negative Breast Cancer | Breast Cancer | phase-2 | pCR rates in study arms A and B were similar (65.7% and 69.0%, respectively). | Source → |
| Cost-effectiveness of Atezolizumab for Lung Cancer Patients | Lung Cancer | phase-3 | Adding atezolizumab to chemotherapy increased QALYs by 0.721 at an incremental cost of NT$2,111,359. | Source → |
| Combining Two Treatments May Help Fight Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Atezolizumab Compared to Docetaxel in Lung Cancer Treatment | Lung Cancer | meta-analysis | Atezolizumab had better efficacy than docetaxel for overall survival (HR: 0.77, 95% CI: 0.73 to 0.81). | Source → |
| Atezolizumab treatment may worsen eye problems in some lung cancer patients | Lung Cancer | observational | — | Source → |
| New Cancer Treatment Combination Shows Promise for Melanoma Patients | Melanoma | phase-2 | 12-month EFS was 72.0% (95%CI 57.9-89.5%), 12-month RFS was 73.3% (95%CI 56.9-94.5%), and 12-month DMFS 86.0% (95%CI 72.2-100%). | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.